AlphaQuest LLC Has $2.50 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

AlphaQuest LLC increased its position in Boston Scientific Co. (NYSE:BSX) by 57.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,958 shares of the medical equipment provider’s stock after buying an additional 10,172 shares during the quarter. Boston Scientific accounts for approximately 0.3% of AlphaQuest LLC’s investment portfolio, making the stock its 29th largest position. AlphaQuest LLC’s holdings in Boston Scientific were worth $2,497,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. TFC Financial Management Inc. lifted its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 210 shares during the period. Dunhill Financial LLC grew its holdings in Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 152 shares during the period. Global Wealth Strategies & Associates increased its position in Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $29,000. Finally, Capital Performance Advisors LLP acquired a new position in Boston Scientific during the third quarter worth $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $99.15 on Friday. The stock’s 50-day simple moving average is $100.45 and its 200 day simple moving average is $91.19. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17. The stock has a market capitalization of $146.33 billion, a price-to-earnings ratio of 79.32, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BSX. Citigroup increased their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Raymond James boosted their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. Barclays increased their price target on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Canaccord Genuity Group boosted their price objective on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Argus set a $130.00 target price on Boston Scientific in a research report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $108.91.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares in the company, valued at $2,966,329.50. This represents a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 137,322 shares of company stock valued at $14,321,068. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.